Skip to content

Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock

A Multi-center Randomized Comparison of a Minimally-invasive Cardiovascular Hemodynamic Optimization (MiCHO) Protocol Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock Patients Presenting to the Emergency Department

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00535821
Acronym
MiCHO
Enrollment
5
Registered
2007-09-26
Start date
2007-06-30
Completion date
2010-09-30
Last updated
2014-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock, Severe Sepsis

Keywords

Emergency Department, Hemodynamic Optimization, Esophageal Doppler monitoring, Early Goal-Directed Therapy

Brief summary

Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality. However, this approach requires invasive hemodynamic monitoring, thus limiting its widespread application in the emergency department setting. A minimally invasive protocol utilizing esophageal Doppler monitoring (EDM) may be of benefit and practical if it is shown to result in similar outcome as EGDT.

Interventions

DEVICEEsophageal Doppler monitoring - CardioQ, Deltex Inc

6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM

DEVICECentral line with CVP and continuous ScvO2 monitoring

6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring

Sponsors

University of Massachusetts, Worcester
CollaboratorOTHER
Wayne State University
CollaboratorOTHER
VA Loma Linda Health Care System
CollaboratorFED
Loma Linda University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients \>= 18 years old * Source of infection * Two or more of systemic inflammatory response syndrome criteria * Systolic blood pressure \< 90 mmHg after a fluid bolus OR lactate \>= 4 mmol/L * A central line has been placed for CVP/ScvO2 monitoring

Exclusion criteria

* Pregnancy * Acute stroke * Acute cardiogenic pulmonary edema * Status asthmaticus * Unstable cardiac dysrhythmia * Active hemorrhage * Acute seizure * Drug overdose * Trauma * Requiring immediate surgery * Do-not-resuscitate status

Design outcomes

Primary

MeasureTime frameDescription
MortalityhospitalIn-hospital mortality

Countries

United States

Participant flow

Participants by arm

ArmCount
MiCHO
A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM) Esophageal Doppler monitoring - CardioQ, Deltex Inc: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
2
EGDT
A 6-hour resuscitation protocol utilizing CVP/ScvO2 Central line with CVP and continuous ScvO2 monitoring: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
3
Total5

Baseline characteristics

CharacteristicMiCHOEGDTTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants0 Participants2 Participants
Age, Categorical
Between 18 and 65 years
0 Participants3 Participants3 Participants
Age, Continuous81.5 years
STANDARD_DEVIATION 10.5
60.7 years
STANDARD_DEVIATION 1.2
69.0 years
STANDARD_DEVIATION 6.1
Region of Enrollment
United States
2 participants3 participants5 participants
SBP < 90 or Lactate >= 4 mmol/L2 participants3 participants5 participants
Sex: Female, Male
Female
0 Participants1 Participants1 Participants
Sex: Female, Male
Male
2 Participants2 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 20 / 3
serious
Total, serious adverse events
0 / 20 / 3

Outcome results

Primary

Mortality

In-hospital mortality

Time frame: hospital

ArmMeasureValue (NUMBER)
MiCHOMortality0 participants
EGDTMortality0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026